P
P

Pfizer

News

British Business - July 28

July 28 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - The largest investor in WM Morrison Supermarkets Plc MRW.L , Silchester International Investors, said it is 'not inclined' to support a 6.3 billion pounds ($8.74
A
P
T

Antibodies from Sinovac's 19 shot fade after about 6 months, booster helps - study

(Updates with study details, comment from Philippine health official, background) BEIJING, July 27 (Reuters) - Antibodies triggered by Sinovac Biotech's SVA.O COVID-19 vaccine declined below a key threshold from around six months after a second dose for most recipients, although a third shot had a strong booster effect, according to a lab study. Ch
P

S.Korea begins 19 vaccination for chip, electronics workers

By Sangmi Cha SEOUL, July 27 (Reuters) - South Korea on Tuesday launched COVID-19 vaccinations for workers at key computer chip and electronic businesses to minimise disruptions in the global supply chain amid struggles to keep up with its inoculation schedule. Major tech companies including Samsung Electronics Co Ltd 005930.KS , Samsung Display Co
P

S.Korea says Moderna reports 'production issue' as vaccination widens to 50s

(Updates with Moderna production issue) By Sangmi Cha and Hyonhee Shin SEOUL, July 26 (Reuters) - South Korea said on Monday it has been informed by Moderna MRNA.O of an unspecified production issue involving its COVID-19 vaccine, as the country expands its inoculation campaign for people aged 55-59 amid a fourth wave of infections. It was not imme
P

Aspen to start J&J 19 vaccine supplies to South Africa from Monday

JOHANNESBURG, July 26 (Reuters) - South Africa's Aspen Pharmacare APNJ.J will supply the first batch of Johnson & Johnson JNJ.N COVID-19 vaccine to the country from July 26, the drugmaker said on Monday. It will be the first set of vaccines to be manufactured in the country from active pharmaceutical ingredients (API) - substances used to make the
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.